drugset

drugset / Trial / NCT01623622

Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke

NCT01623622 ↗

Phase 2 Completed 270 enrolled Asahi Kasei Therapeutics Corporation

RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to investigate the efficacy and safety of HC-58 in patients with severe upper limb hemiplegia following stroke.

Timeline

Start: 2012-07
Primary completion: 2015-05
Completion: 2015-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CALCITONIN EEL	Protein / enzyme biologic	—	—

Indications